In tabling Budget 2021, Finance Minister Tengku Datuk Seri Zafrul Tengku Abdul Aziz said the government was committed to acquiring Covid-19 vaccines through its participation in Covid-19 Vaccine Global Access (Covax), with an estimated cost of over RM3 billion.
The survey, which was released on Thursday (5 November) by the market research company Ipsos in conjunction with the World Economic Forum, found there is a growing reluctance to receive a vaccine, with a decline in vaccine intent found in 10 of the 15 countries surveyed.
Almost half of adults globally said they would get vaccinated within three months of a COVID-19 vaccine being available to all, but this figure dropped to fewer than four in 10 in France and Spain.
Four out of five people in India, China, South Korea, and Brazil said that they would get a vaccine if available compared to just over half in France and about two in three in the US, Spain, Italy, South Africa, Japan, and Germany, as per the report. In that survey, 77 percent of adults were willing to take a shot of COVID-19 vaccine when it becomes available.
He said, "Whenever the vaccine is ready, the Serum Institute of India will give us 30 million doses in the first phase".
Women's T20 Challenge: Trailblazers made small mistakes against Supernovas - Deepti Sharma
However, after the dismissal of these three, the innings of Supernovas stumbled and suddenly the team's score also stopped. After posting a challenging 146/6 wickets, Supernovas restricted their opponents to 144/5 wickets in 20 overs.
Also, 10 per cent of people said that the vaccine is unlikely to be effective.
The same data also showed that the vaccine had low reactogenicity in older adults, meaning that they developed few side-effects. 34 per cent of the people surveyed expressed vaccine confidence concerns are around side effects.
The vaccine entered its third phase of testing in September. It is critical that governments and the private sector come together to build trust in the next steps. One is Sputnik V developed by the Gamaleya National Research Institute of Epidemiology and Microbiology in Russian Federation and the other is EpiVacCorona developed by the Vector State Virology and Biotechnology Center in Siberia.
The CEO of pharmaceutical company AstraZeneca has said his company's coronavirus vaccine candidate could be ready for use by the end of December, pending regulatory approval.
Indian firm Bharat Biotech, which is developing indigenous vaccine "COVAXIN" with the Indian Council of Medical Research (ICMR), is also expected to be launched by the beginning of next year.